文献速递前列腺癌

阿昔替尼联合ADT术前治疗淋巴结转移性前列腺癌的随机2期试验

Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis.
PubMed 文献 · Eur Urol Oncol · 2025-07-12

该随机2期试验纳入73例新诊断伴淋巴结转移的前列腺癌患者,术前接受ADT联合或不联合阿昔替尼治疗,主要终点为术后1年无治疗失败率。在55例淋巴结阳性患者中,联合组成功率为36.8%,单用ADT组为19.0%,联合组至进展中位时间更长(9.8个月 vs 5.7个月,p=0.03),但总体疗效有限。

要点

  • 术前阿昔替尼联合ADT较单用ADT可能提高淋巴结阳性前列腺癌患者的术后无治疗失败率。
  • 联合组至进展中位时间9.8个月,显著长于单用ADT组的5.7个月(p=0.03)。
  • 联合方案未出现4-5级毒性或意外围手术期并发症,但总体疗效有限。

核心结论

  • 在新诊断伴淋巴结转移的前列腺癌患者中,术前阿昔替尼联合ADT策略可行,且较单用ADT更可能获得显著的无治疗间期,但总体疗效有限,需优化患者选择和更有效的联合方案。

研究设计与样本

  • 随机2期试验,纳入73例新诊断前列腺癌伴临床淋巴结转移(cTxN1M0或cTxNxM1a)或亚临床淋巴结转移极高风险患者,先接受2个月ADT,随后按2:1随机分配至阿昔替尼联合ADT组(49例)或继续ADT单药组(24例),治疗4个月后手术并停止全身治疗。

主要发现

  • 在55例淋巴结阳性患者中,阿昔替尼联合ADT组成功率为36.8%(95%可信区间22.5-52.5%),ADT单药组为19.0%(95%可信区间5.7-37.9%),联合组成功率更高的概率为0.935。
  • 联合组至进展中位时间为9.8个月(95%置信区间7.6-17.4),ADT单药组为5.7个月(95%置信区间4.0-11.3),p=0.03。
  • 两组病理缓解、至转移进展时间和总生存相似,未出现4-5级毒性或意外围手术期并发症。

关键数值与推荐

  • 成功定义为术后1年无治疗失败,失败标准为前列腺特异性抗原>1.0 ng/ml、客观进展或启动额外治疗。

临床怎么用

  • 对于新诊断伴淋巴结转移的前列腺癌,术前阿昔替尼联合ADT可作为探索性策略,但需注意总体疗效有限,不应作为常规推荐。

局限性

  • 样本量较小(共73例),且为2期试验,结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Strategies that combine systemic and locoregional therapies are increasingly used in prostate cancer (PC) with lymph node metastasis (LNM) at presentation. We investigated whether the presurgical combination of androgen deprivation therapy (ADT) and the antiangiogenic agent axitinib would be more effective than ADT alone in achieving time off systemic therapy after surgery in these patients. METHODS: Patients with newly diagnosed PC with either clinically detected LNM (cTxN1M0 or cTxNxM1a) or at very high risk for subclinical LNM were treated with ADT for 2 mo and then randomized 2:1 to addition of axitinib to ADT versus continuing ADT alone for an additional 4 mo before surgery and discontinuation of systemic therapy. The primary endpoint was the rate of freedom from treatment failure in the intention-to-treat population at 1 yr postoperatively ("success"). Failure was defined as prostate-specific antigen >1.0 ng/ml, objective progression, or initiation of additional treatment. KEY FINDINGS AND LIMITATIONS: Of the 73 patients accrued, 49 received axitinib + ADT and 24 received ADT alone. Of the 49 patients who had surgery on protocol, success was achieved in 26, of whom 22 received axitinib + ADT and four received ADT alone. In the node-positive group of 55 patients, the success rate was 36.8% (95% credible interval [CrI] 22.5-52.5%) for axitinib + ADT and 19.0% (95% CrI 5.7-37.9%) for ADT alone; the probability of a higher success rate with axitinib + ADT was 0.935. The median time to progression was 9.8 mo (95% confidence interval [CI] 7.6-17.4) with axitinib + ADT versus 5.7 mo (95% CI 4.0-11.3) with ADT alone (p = 0.03). Pathologic responses, time to metastatic progression, and overall survival were similar between the arms. There were no grade 4-5 toxicities or unexpected perioperative complications. CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with newly diagnosed PC with LNM, a presurgical strategy that combines axitinib + ADT was feasible and was more likely than ADT alone to achieve significant time off treatment. However, the overall efficacy was limited, suggesting that patient selection and more effective combinations are needed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Zurita AJ, Tidwell RS, Chapin BF, et al. Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis. Eur Urol Oncol. 2025. PMID: 40651932. doi:10.1016/j.euo.2025.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。